Nephrotoxicity Biomarkers To Be Test Run For FDA Qualification Program
Executive Summary
ATLANTA - A set of nephrotoxicity biomarkers will be the first submission considered by an FDA pilot program for qualifying biomarkers
You may also be interested in...
Biomarker Qualification Should Be Multi-Step Process, Regulators Say
U.S. and European regulations expect qualification of biomarkers for clinical use to be a multi-stage process that incrementally broadens a marker's application
Biomarker Qualification Should Be Multi-Step Process, Regulators Say
U.S. and European regulations expect qualification of biomarkers for clinical use to be a multi-stage process that incrementally broadens a marker's application
Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says
FDA Commissioner Margaret Hamburg said that working within the current regulatory framework rather than seeking new statutory authority to address the development of drugs and accompanying diagnostic tests would be preferable to address personalized medicine questions at the agency